Edison Goncalves, MD
Endocrinology, Diabetes & Metabolism · Birmingham, ALNPI 1457309593
Payments from drug & device makers
Across 507 payments — averaging $279.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$134K
- Johnson & Johnson$3K
- AstraZeneca$750
- Corcept Therapeutics$560
- Dexcom, Inc.$504
- Sanofi-aventis U.S. LLC$375
- plus $3K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 250 | $134,124 |
| Johnson & Johnson | 17 | $2,844 |
| AstraZeneca | 32 | $750 |
| Corcept Therapeutics | 28 | $560 |
| Dexcom, Inc. | 26 | $504 |
| Sanofi-aventis U.S. LLC | 22 | $375 |
| Abbott | 15 | $326 |
| Novartis | 20 | $276 |
| AbbVie | 15 | $266 |
| Boehringer Ingelheim | 5 | $207 |
| Amgen(2 entities) | 12 | $184 |
| Merck | 5 | $167 |
| Lilly USA, LLC | 9 | $158 |
| Medtronic(2 entities) | 7 | $143 |
| Kowa Pharmaceuticals America, Inc. | 2 | $132 |
| IBSA Pharma Inc. | 7 | $131 |
| Mannkind Corporation | 7 | $122 |
| Tandem Diabetes Care, Inc. | 6 | $117 |
| Janssen Scientific Affairs, LLC | 1 | $110 |
| BETA Bionics, Inc. | 5 | $106 |
| Xeris Pharmaceuticals, Inc. | 3 | $62 |
| Antares Pharma, Inc. | 2 | $40 |
| Shire North American Group Inc | 2 | $40 |
| Radius Health, Inc. | 1 | $33 |
| Amarin Pharma, Inc. | 2 | $31 |
| Bayer | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Averitas Pharma Inc. | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Eisai Inc. | 1 | $12 |
How this compares
$141,918 in reported general payments places this provider in the 85th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Birmingham
- William GarveyBirmingham$3.8M
- Fernando OvalleBirmingham$516K
- Ralph TeagueBirmingham$487K
- Amy WarrinerBirmingham$182K
- Fernando BrilBirmingham$74K
- Tom VaughanBirmingham$68K
- Rodrigo ValderramaBirmingham$61K
- Janelle TownesBirmingham$56K
- Richard RosenthalBirmingham$24K
- Ananda BasuBirmingham$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.